FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Peterson Kristine						2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
						3. Date of Earliest Transaction (Month/Day/Year) 06/17/2020									Officer below)	(give title		Other (s below)	pecify	
(Street) NEWTO (City)			18940 (Zip)		4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					action	ction 2A. Deemed Execution Date,			3. Transad	4. Securi	ties Acqui d Of (D) (In	red (A) c	or 5. Amou 4 and Securiti Benefici		nt of s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	or Prio	rice (Instr. 3		ction(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Dat urity or Exercise (Month/Day/Year) if any			Date,	4. Transa Code (I 3)		n of		6. Date Exe Expiration (Month/Da	Date		e and 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		5	8. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		expiration bate	Title	Amou or Numb of Share	ber						
Deferred Share Unit	\$0 ⁽¹⁾	06/17/2020			Α		17,000		(3)(2)		(2)	Commor Stock ⁽²⁾	17,0	00	\$0 ⁽¹⁾	44,954	4	D		
Stock Option (right to buy)	\$4.56	06/17/2020			A		50,000		(4)	0	6/17/2030	Commor Stock	50,0	00	\$4.56	50,000	0	D		

Explanation of Responses:

1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

2. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

3. The deferred share units vest quarterly on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date.

4. Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date.

/s/ David G. Foster, attorney in 06/18/2020 <u>fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.